Clinical Trials Logo

Clinical Trial Summary

The prognosis of Diffuse Large B cell Lymphoma (DLBCL) patients with an early relapse is dismal. Atezolizumab has shown promising activity in relapsed DLBCL patients. Toxicity data on atezolizumab are available for > 6000 patients and is manageable. The assumption of this study is that atezolizumab consolidation will result in higher disease free survival by eradicating minimal residual disease In melanoma and lung cancer consolidation immunotherapy after chemoradiotherapy has shown an increase in survival.

Clinical Trial Description

In high risk diffuse large B-cell lymphoma (DLBCL), International Prognostic Index (IPI)-score ≥ 3 21% of patients will relapse within 2-years after completion of R-CHOP induction treatment despite achieving a complete remission. Patient relapsing within a year after R-CHOP treatment have a very poor prognosis, even after second line chemotherapy, with only 15% of patients achieving a long remission. Therefore, additional therapy in first line treatment is required for these patients. The immune checkpoint inhibitor atezolizumab is a monoclonal antibody directed against the program death ligand 1 (PDL1). The PD1 and PDL1 inhibitors have shown excellent results in relapsed Hodgkin lymphoma and promising results in relapsed B-cell non Hodgkin lymphoma. Given the acceptable toxicity profile of atezolizumab, this study examines the efficacy and toxicity of atezolizumab as consolidation treatment after R-CHOP induction in DLBCL patients at high risk of relapse. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03463057
Study type Interventional
Source Stichting Hemato-Oncologie voor Volwassenen Nederland
Contact M. Nijland, MD
Phone +31 50 3611761
Status Recruiting
Phase Phase 2
Start date August 30, 2018
Completion date April 2025

See also
  Status Clinical Trial Phase
Completed NCT00333190 - CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation N/A
Recruiting NCT03535753 - Safety and Efficacy Evaluation of Decitabine With R-GDP Phase 1
Completed NCT00513175 - Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia N/A
Completed NCT00342121 - Influence of Corn Farming on the Immune System
Active, not recruiting NCT01101581 - Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL Phase 1/Phase 2
Not yet recruiting NCT03789240 - Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma Phase 2
Recruiting NCT02702492 - PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) Phase 1
Recruiting NCT03527147 - Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) Phase 1
Terminated NCT00814983 - Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft Phase 1/Phase 2
Completed NCT00891592 - Umbilical Cord Blood Transplant for Hematological Malignancies Phase 1
Completed NCT00546793 - Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL Phase 1/Phase 2
Not yet recruiting NCT02847949 - A Study of IGN002 for Refractory NHL Phase 2
Recruiting NCT03739502 - A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant Phase 2
Recruiting NCT02315612 - Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies Phase 1
Recruiting NCT00515892 - Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease Phase 1
Completed NCT00421395 - Safety Study of NHL With 90Y-hLL2 IgG Phase 1/Phase 2
Recruiting NCT03465540 - Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Multiple Myeloma, NHL, and AML Phase 1
Terminated NCT02110563 - Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma Phase 1
Terminated NCT00471367 - Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877 Phase 1